This is the text extract for September Tender Notification; Contact: Notifications, browse documents here.

---

30 September 2011

TENDER RESULTS

The PHARMAC Board (or Chief Executive under Delegated Authority) has resolved to award tenders for Sole Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and the 2009/10 Invitation to Tender, dated 4 December 2009. As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A456574 - qA18036

Page 1 of 3

---

2010/11 Tender – Sole Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Oint BP; 500 g pot Current New subsidy subsidy and and price price $5.11 $3.83 Sole supply brand (Supplier) Multichem (Multichem) Date of listing/subsidy change for tender winning brand 1 March 2012 Date of reference pricing of other listed brands 1 May 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 August 2012 PSM (API)

Zinc and Castor Oil

2009/10 Tender – Sole Supply Status or Hospital Supply Status applies until 30 June 2013 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Cap hydrochloride 150 mg; 16 capsules, blister pack Current New subsidy subsidy and and price price $11.39 $9.90 Sole supply brand (Supplier) Clindamycin ABM (ABM) Date of listing/subsidy change for tender winning brand 1 March 2012 Date of reference pricing of other listed brands 1 May 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 August 2012 Dalacin C (Pfizer)

Clindamycin

A4565740317 - qA18036

Page 2 of 3

---

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Cap hydrochloride 150 mg; 16 capsules, blister pack Current pack price $11.39 New pack price $9.90 Hospital Supply Brand (Supplier) Clindamycin ABM (ABM) DV Limit 1% Date of listing/price change for tender winning brand 1 March 2012 Hospital Supply Status date (and delisting of other listed brands) 1 May 2012 Brand (Supplier) to be delisted Dalacin C (Pfizer)

The decisions were as follows:

Chemical Name

Clindamycin

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name Cefepime hydrochloride Cefepime hydrochloride Domperidone Line Item Inj 1 g Inj 2 g Tab 10 mg Chemical Name Quinapril Quinapril Quinapril Line Item Tab 5 mg Tab 10 mg Tab 20 mg

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A4565740317 - qA18036

Page 3 of 3